HOME >> MEDICINE >> NEWS
Treatment has demonstrated improvement in physical function and kept joint damage from progressing

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., November 13, 2005 Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced data from a long-term blinded study of anti-TNF agent in patients with rheumatoid arthritis (RA) demonstrated that more than three quarters of patients treated with Enbrel (etanercept) plus methotrexate combination therapy experienced no progression of joint damage at three years. These new results from the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study will be presented at the American College of Rheumatology's (ACR) Annual Scientific Meeting in San Diego, California.

"Rheumatoid arthritis is a chronic condition requiring long-term treatment. It is critical to provide patients with treatment options that not only reduce the signs and symptoms of the disease, but also inhibit the progression of joint damage," said Dsire van der Heijde, M.D., professor of rheumatology, University of Maastricht in the Netherlands. "The TEMPO results reinforce the benefits of ENBREL and methotrexate combination therapy and underscore the importance of effective treatment."

At three years, the majority of patients taking ENBREL and methotrexate combination therapy had no progression of joint damage. These results were significantly better than those achieved in ENBREL monotherapy and methotrexate monotherapy-treated patients. Patients receiving ENBREL monotherapy also had significantly better results than patients receiving methotrexate monotherapy. Total Sharp Score was calculated by assessing changes in joint space narrowing and bone erosion as captured by radiographic imaging.

Further, additional data presented at ACR showed that improvement in physical function was higher for the ENBREL combination group than for either therapy alone. Patients treated with ENBREL combination therapy experienced a 56 percent mean improvement in Health Assessment
'"/>

Contact: Christine Cassiano, Amgen
805-447-4587
Porter Novelli
15-Nov-2005


Page: 1 2

Related medicine news :

1. Treatment for early prostate cancer associated with type of specialist seen
2. Treatment outcomes of patients with HIV and tuberculosis
3. Treatment of kidney condition requires an individualized approach
4. Treatment of in-hospital cardiac patients is focus of Jefferson University presentations
5. Treatment for homeless youth pays off in long run, study finds
6. Treatment discovered for deadly childhood disease
7. Treatment developed for patients with medically unexplained symptoms
8. Treatment drug may cause jawbone to die
9. Treatment for anorexia nervosa appears to have improved outcome
10. Treatment reduces gastric ulcers in at-risk patients using long-term NSAIDS
11. North Central Cancer Treatment Group finding ways to make treatment easier

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/3/2016)... ... May 03, 2016 , ... ... creative director Joe Ferrazano to serve in the newly created position of executive ... overseeing the agency’s creative efforts in the Chicago and LA offices. He reports ...
(Date:5/3/2016)... CA (PRWEB) , ... May 03, 2016 , ... ... accredited American online university, has announced today the launch of its Associates and ... Laureate and President Emeritus of The Rockefeller University, Dr. Torsten N. Wiesel; Chairman ...
(Date:5/3/2016)... Toledo, OH (PRWEB) , ... May 03, 2016 , ... ... remain a leading cause of death across the United States and account for one ... physical and mental impairments or are permanently disabled. HCR ManorCare is launching a video ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... Canada’s top Information and Communication Technology (ICT) companies in the annual Branham300 listing. ... companies operating in Canada, as ranked by revenue. , “We are honored ...
(Date:5/3/2016)... Miami, FL (PRWEB) , ... May 03, 2016 , ... ... support both its Grow & Climb children and youth programs in South Miami. Macy’s ... several years. , The Grow Program provides afterschool tutoring, mentoring, enrichment and academic ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... April 29, 2016  In the next ten ... shift from systems dependent on CRTs monitors to those ... modality CRT Medical monitors and will automatically sync ... host of foreseeable benefits to this technological advancement, ... modalities have to be replaced in order to ...
(Date:4/29/2016)... Glycotope GmbH, a clinical-stage immuno-oncology ... appointment of Dr. Alfredo Zurlo as Chief ... with many years clinical experience and a proven track ... role was at Mologen AG where he was Chief ... Dr. Zurlo held various positions at F Hoffmann La ...
(Date:4/28/2016)... April 28, 2016 Research and ... Plastic Surgery Products Market 2016-2020" report to their ... , The global plastic surgery products market ... during the period 2016-2020. , ,The growing adoption of ... the growth of the market. Lasers are used to ...
Breaking Medicine Technology:
Cached News: